QTRX

Thank you for standing by. Welcome to Quanterix Corporation Q1 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. Thank you. I would now like to turn the conference over to Joshua Young. You may begin.

Thank you, Priscilla, and good afternoon, everybody. With me on today's call are Everett Cunningham, Quanterix President and CEO, and Vandana Sriram, Quanterix Chief Financial Officer. Today's call is being recorded, and a replay of the call will be available on the investors section of our website. During the course of today's presentation, we will make forward-looking statements covered under the U.S. Private Securities Litigation Reform Act. These forward-looking statements are based on management's beliefs and assumptions as of today, May 6, 2026. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

To supplement our financial statements presented on a GAAP basis, we have provided certain non-GAAP financial measures. These non-GAAP measures are used to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that such measures are important in comparing current results with other periods' results and assessing our operating performance within our industry. Non-GAAP financial information presented herein should be considered in conjunction with, not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures set forth in the presentation posted to our website and in the earnings release issued today. Finally, any percentage changes we discuss will be on a year-over-year basis unless otherwise noted.

Now I'd like to turn the call over to Everett Cunningham. Everett.

Thanks, Josh. Hey, I'm happy to be here with all of you this afternoon. My time at the company has been very exciting and informative, and I'm more confident than ever about the future of Quanterix. In that spirit, I'd like to start off by sharing some of my key observations in my first 100 days with the company. First, we have a passionate employee base full of people who want Quanterix to win and be successful for the long term. Based on our customers' feedback, we remain the market leader in early detection of critical disease biomarkers, and that's a great position to be in, one that we must capitalize on. We have an install base of over 2,300 instruments across passionate customers who appreciate the value of our products and services.

Our market-leading technologies include Simoa, where we are the leaders in ultrasensitive digital immunoassays for protein biomarker quantification, and spatial, where we have the highest plex proteomic platform on the market. These are both businesses where we can generate strong growth and build solid businesses moving forward. Our strong foundation positions us to be a leader in the Alzheimer's diagnostics industry. It's early innings, but I believe in our capabilities, and I want to invest in them now. In summary, I believe that we have a clear path towards profitability for our research tools business and a balance sheet to support our growth ambitions for our Alzheimer's disease diagnostics with approximately $100 million in cash and no debt. This journey I'm here to undertake is exciting, and I couldn't be more excited to be here.

Now, moving from a high-level observation to more of a detailed strategic and tactical consideration, I've gathered a lot of feedback in my first three months here. The company has many strengths to build upon, but we're not currently fulfilling our potential. As a result, I'm making some operational as well as strategic changes now and in the future quarters that will help us better capitalize on our compelling opportunities. One overriding philosophical change that we must move the company from a mode of integrating and realizing synergies to a mode of investing and growing our business for long-term growth. We are allocating resources to growth opportunities where we see compelling near-term returns while ensuring that we continue to hit our annual operating targets in 2026 and beyond, just as we delivered our $85 million of cost synergies from the Akoya acquisition.

In the first quarter of 2026, we reported $36.4 million in revenue as our end markets remained difficult. While our consumable revenues performed as planned, our revenues from our instrumentation business was slightly softer than expected. Some of the shortfalls related to timing issues, but there's also some changes that we're gonna be implementing to bring more focus to our sales efforts. These changes will bring benefits as the year progresses. In addition to investing in growth opportunities, we are hard at work at creating a culture of operational execution and delivering quarterly expectations as a key tenet of our organization we are building here at Quanterix. We've established good operational rigor, which can be seen in our gross margin performance, our disciplined approach to spending, and in our ability to consistently hit our cash usage targets.

During the last call, I shared details of my 30-year commercial background at companies such as Illumina, Quest Diagnostics, and Exact Sciences. I know what best-in-class commercial organizations look like, and I've identified multiple opportunities to take Quanterix to the next level of operational performance. As a result, we're making several investments to improve our commercial effectiveness in 2026 and beyond. These investments include, we're going to elevate our pharma partnerships and our accelerator business with an experienced senior leader. This important business has slipped in recent quarters, and we are changing that now. I expect that myself, the new leader, and our current professionals in this space will have frequent and candid dialogues with our pharma clients to understand how we can better solve for their needs. With our best-in-class technology and solutions, we expect significant improvement this year.

We are expanding our team of lead generation representatives to improve our outbound targeting and drive net new business. We are also going to hire new market development leaders that will support the sales team in training, systematic value propositions, and competitive positioning. This is intended to refocus our sales force on their customers while clarifying Quanterix's many advantages of our overall value propositions in our TN markets. We will be harder hitting on differentiation. For example, we will highlight our ability to detect proteins more accurately than others while doing it more consistently. We are leveraging Thermo Fisher's distribution capabilities to improve our online presence. This will have a dual benefit of helping our customers by easing their barriers to access for our products while reducing the manual work of our commercial team to provide pricing quotes.

Everything that we're doing is centered on investments that will yield near-term returns to sharpen our focus, expand our opportunity set, and grow our top-line performance in 2026 and beyond. Now, our customers have told me repeatedly that we are the market leader. Armed with this feedback, we're adjusting our course, and importantly, we're moving quickly with a sense of urgency. Now, we're also increasing our investment in our Alzheimer's diagnostics business. Healthcare providers who treat Alzheimer's want a reliable, non-invasive test to drive earlier intervention of this terrible disease. We firmly believe, and industry leaders concur, that we have the best performing and most comprehensive Alzheimer's diagnostics test available today in LucentAD Complete, and we expect to garner meaningful market share as blood-based biomarker testing continues to grow. We're making the following investments in our diagnostics business.

We are hiring a new diagnostics leader, reporting directly into me, to build and invest in our emerging diagnostics business. With this move, we are bringing in strong leadership to expand and strengthen our diagnostics portfolio as part of our commitment to advancing our position in the nascent Alzheimer's testing market. We are upgrading our next-generation Simoa HD-X platform and expect to file for IVD status with the FDA in 2027. This will position us not only to serve research customers who increasingly request IVD solutions for their clinical trials, but it will also set us up to support the distributed IVD model for our lab customers.

Next, we are investing in lab infrastructure and implementing new targeted sales and marketing tactics to increase mind share for our LucentAD Complete test in anticipation of FDA clearance in the second half of this year. These investments will build on the strong momentum that we have in our diagnostics business. As a matter of fact, today, we just announced an important and exciting partnership with Tempus AI. Under this agreement, LucentAD Complete will be integrated into EHR systems at select Tempus Partner Health system locations as part of the Tempus Next program. Patients who meet the clinical criteria will be flagged using a proprietary algorithm, and testing will be available for order at a clinician's discretion. To help fund these investments, we're streamlining our product roadmap.

My engagement with customers and collaborators in this sector over the past three months has led us to prioritize our Simoa HD-X platform and other investments, both on the research tools and diagnostic sides of the business. We're incorporating learnings and enhancements from our next-generation platform into the HDX upgrade. Additionally, we are continuing to gather feedback from our early access launch program that we expect to incorporate over time into the next-generation Simoa program. On the spatial side of our business, our two key priorities for 2026 are to expand our PhenoCode biomarker panels for discovery applications and to release new reagents for the AT platform to better support clinical applications. From a financial perspective, we continue to expect to reach cash flow breakeven performance by the fourth quarter this year.

The entire company is committed to building a profitable and sustainable research tools business that are leaders in both spatial and ultrasensitive proteomics. We expect the investments that I discussed today will help drive commercial effectiveness in the second half of 2026. We are not waiting for better markets. Instead, we're making thoughtful and deliberate decisions to drive Quanterix to where the industry is going. Finally, we are excited about our diagnostics business as we are delivering on key milestones this year, while welcoming in a proven, seasoned business leader to accelerate our performance in this space. Let me turn it over to our Chief Financial Officer, Vandana Sriram.

Thank you, Everett, good afternoon. Total revenue for the first quarter was $36.4 million, an increase of 20% from the previous year. Organic revenue declined by 21%. Revenue from our diagnostics partners was $2.9 million, up meaningfully year-over-year from $1.6 million in the first quarter of 2025. This reflects increasing volume for our single biomarker test from our diagnostics enablement partners. During the quarter, both of our end markets and our consumables revenue were largely in line with our expectations, but we saw slightly weaker than expected results in instrumentation, with a handful of instrument transactions getting pushed into the second quarter. From a product perspective, Simoa contributed $24 million, a 21% organic revenue decline, and spatial reported $12.4 million, down 26% year-over-year.

Instrument revenue was $4 million, comprised of $2.3 million from Simoa and $1.7 million from spatial instruments. We placed 16 Simoa and 11 spatial instruments in the quarter. Consumables revenue was $21.4 million. This consisted of $14.5 million in Simoa and $6.9 million in spatial consumables. Accelerator lab services were $4.3 million, $3.5 million in Simoa, and $800,000 in spatial. Our customer mix was meaningfully skewed to academia, which represented approximately 65% of the business in Q1. On a pro forma basis, assuming Quanterix and Akoya were combined for the full year, academic revenue for the first quarter declined approximately 16%. Pharma revenue declined 33% year-over-year, primarily due to fewer large accelerator projects and spatial instruments placed.

As Everett already mentioned, we are adding resources and refocusing strategies towards the pharma end market. We expect to see better results here in the coming quarters. Moving on to the P&L. Gross profit and margin for the first quarter were $15.6 million or 42.7%. Non-GAAP gross profit was $18.5 million. Non-GAAP gross margin was 50.9%. The synergies from the Akoya transaction are apparent here. Even with a reduction in pro forma revenue, we are maintaining non-GAAP gross margin over 50%. Operating expenses for the quarter were $56.9 million. Included in operating expenses are approximately $22 million of costs related to acquisition, integration, restructuring, and purchase accounting. Notably, this includes a $19 million one-time write-off from an intangible asset related to the termination of an Akoya Biosciences development agreement.

Offsetting this, other income contains $22 million of liabilities written off, resulting in net non-cash income of $2.3 million from this termination. Non-GAAP operating expenses were $34.7 million, a decrease of roughly $2.3 million sequentially as a result of the synergies. We are now operating the new Quanterix entity at roughly the same level of operating expenses we had when we were a standalone company. As Everett mentioned, as a result of the Akoya integration actions taken to date, at the end of Q1, we have delivered the $85 million of annualized cost synergies that we committed to as part of the acquisition. The combined entity is operating as expected, and while there are a few remaining actions to complete, we will not continue to report these synergies after this quarter.

Our adjusted EBITDA was a loss of $9.8 million, a sequential improvement of $1.5 million despite lower revenues versus the prior quarter. We ended the quarter with $102.6 million of cash equivalents, marketable securities and restricted cash. During the quarter, we used $19 million of cash, of which $4.2 million was related to one-time integration and employee-related costs. Adjusted cash usage during the quarter was $14.7 million. The first quarter is our highest quarter of cash usage, similar to many companies, due to approximately $11 million of annual payments such as insurance renewals and annual bonuses. We look ahead, we expect our cash usage to move meaningfully lower as these annual payments are behind us and we make progress towards our cash flow breakeven target. Turning to guidance for 2026.

We are maintaining our guidance for the full year 2026, and we continue to expect to report approximately $169 million-$174 million of revenue. We expect GAAP gross margin to be in a range of 41%-45% and non-GAAP gross margins to be in a range of 49%-53%. In the first quarter, we changed our accounting policy for classifying shipping and handling costs for product sales to record them within gross margin. Historically, they were recorded in SG&A expenses. We believe this classification is preferable because it better aligns costs with related revenue and is consistent with our peers. We reflected this reclassification in our GAAP margin guidance, but there is no change to the underlying non-GAAP margin expectation.

We continue to anticipate achieving cash flow breakeven in the second half of the year and expect to end the year with cash in the range of $100 million with no debt. Finally, in terms of our quarterly cadence, we expect second quarter revenues to be roughly in line to slightly ahead of Q1, and we expect that the commercial initiatives that we're investing in will help to drive increased revenues in the second half of 2026. I will now turn it back over to Everett for closing remarks.

Thanks, Vandana. You know, we're moving quickly. We're making decisions that will improve our commercial effectiveness, streamline our product management priorities, and also enable Quanterix to capitalize on a compelling opportunity in the Alzheimer's diagnostics market. We're doing all this while moving Quanterix closer to cash flow breakeven performance. Now, with that said, I'd like to turn it over back to Josh for questions and answers.

Thank you. Prila, please assemble the Q&A roster.

Your first question comes from the line of Kyle Mikson with Canaccord. Please go ahead.

Hey, guys. Thanks for the questions. Good to hear all these, all these updates here, changes and so forth. I guess, Everett, the one that sticks out to me is the preparation for the IVD submission for HD-X in 2027. I guess, like, the question is kind of like, you know, why do you need IVD for that system? You talked about, I think, pharma important there as well as a distributed model, but, you know, maybe just dive into Is this needed more for, you know, Alzheimer's, neurology or oncology? Is that part of the aspiration here? And then maybe like a decentralization strategy internationally.

It appears that that's in the works as well 'cause, you know, when you think about this compared to some other platforms that we know of, could be interesting to think about long term. Thanks.

I appreciate the question. I can just go back to my last three months of being out in the market, talking to customers. We're investing in our HD-X platform because it's our workhorse. We have a really good, robust install base. It's our largest install base. The timing of it fits nicely to our diagnostics build-out. Also, with making the machine more reliable, it's also going to benefit our research customers too. When we build the machine out, it's for two reasons. First of all, it will solidify our research-only business, it will get us ready for diagnostics, and it will give us what I would just say optionality to have a distributed plan for our lab partners, both domestically and internationally.

That's why we've made the choice of really prioritizing our focus in getting that machine IVD ready in 2027.

Yeah. Okay. That was great. Then maybe just to follow up, what's the status of the Simoa1 platform? Honestly, I think you were talking about like an early access last quarter, and that platform, I believe, was had, you know, some translational use cases, like maybe higher plex. I feel like given this, given the focus on pharma going forward, it could have actually aligned with that. Can you just give us an update there?

Yeah, absolutely. Thanks. We're still very focused on being technology leaders in the marketplace, Simoa1 is part of our next generation. We are still doing early access with Simoa1. We're getting feedback from our customer, and we're looking to take that feedback and actually help us with our HD-X next generation and our HD-X upgrade. Simoa1 still is part of our portfolio, and we're getting really good feedback.

Awesome. Finally, on proteomics competition, relevant recently, obviously. You guys obviously targeting low plex, a little bit of mid plex, and you got the sensitivity advantage that probably is driving, you know, this firm hold on the low plex market, you know, we would hope. Can you just talk about what you're seeing competitively over the last few months and maybe going forward and, just speak to your conviction level that you're gonna maintain this share or increase it?

We feel, and I'll have Vandana help me too, we feel really good about our position in the spatial low plex market. You know, we have 10 times the number of low plex assays available in the marketplace compared to our competition. Our install base in this space is, you know, is larger than our competition. You know, Quanterix focuses on part of the translational research market that includes later-stage clinical trials, of which reproducibility is really, really important. Again, feedback from our customers, we lead in that space. Where I see benefits of our spatial business moving forward, our tools, our technology is market-leading. We're gonna improve our reach to our customers. We're putting in more marketing investments. We have amazing, exciting launches in the spatial space.

We feel that that's gonna give us a boost in the second half. Vandana, I don't know if you wanna mention anything else.

No, I think that's exactly right. You know, on the Simoa front, while there's been a lot of talk of competition, I think, all of the data and all of the research suggests that we have the broadest menu as well as the greatest level of sensitivity, as well as lot-to-lot and lab-to-lab reproducibility versus anyone in the market. On the spatial side, you know, with a concentration both in the research and in the clinical side, there's a lot of exciting things going on there. As Everett said, we're now gonna kind of turbocharge that to make sure we're getting the right share of market that we deserve.

All right. Super helpful, guys. Thanks. Thank you.

The next question comes from the line of Puneet Souda with Leerink Partners. Please go ahead.

Yeah, hi, Everett, and team. Thanks for taking my question. I'll ask my questions in one. First, Everett, great to see the actions you're taking on the diagnostic side, bringing in leadership and investing into that business. Just wanted to get a sense of the level of investment that you need there and how should we expect, you know, what should we expect for Alzheimer's in the overall guide here? This looks like a second half weighted guide, just wanted to get a sense there. Could you maybe also elaborate, you know, as you transition some of the business or the focus from the core tools side to the diagnostic side, is there a chance for any, you know, air pocket?

Obviously, that's a question that we, you know, frequently get from investors. Thank you.

Yeah. Maybe I'll start out with just the diagnostics investment, Puneet. Listen, I feel good about bringing in a seasoned leader. I'll give you a little bit of background. I can't name the person specifically yet, but in a couple of weeks we'll be able to name it. This leader has 25 plus years in diagnostics. I've worked with this leader before. They know not only the sales side, but they know important customers in this space. They've had really good payer and reimbursement interactions. They know the blood-based biomarker business, and so it's like the perfect fit for Quanterix and where we are now. That's one. This person, along with many others here at Quanterix, are gonna help me build out that end-to-end plan.

What we're investing this year I feel is really appropriate. We're adding right now feet on the street that will help us sell LucentAD Complete, and also help with our lab partnership that we have going now. We're investing in clinical utility studies. Those clinical utility studies we'll read out in the second half. We're thinking about what is the next phase that we need also to continue to move this forward. Just, to me, I look at this as a surround sound type thing when I think of diagnostics. Our lab infrastructure needs to be ready for order to cash. We're investing in our lab infrastructure too. We will be ready once we get FDA, you know, clearance in the second half, we will be ready to, what I would say, scale.

The last thing I'll mention for a diagnostic standpoint, and I've always thought this way, even back in my Exact Sciences and Quest Diagnostics days, we're not gonna do this alone. We're gonna have smart, unique partnerships to help us scale this business, and we started now. Our partnership with Tempus AI is a great example of what we're doing and how we're creating scale in the business. We have Life Line Screening. Again, more scale in helping us get our Lucent AD and our LucentAD Complete test out there. We'll do the same once we get FDA clearance of how do we organically build scale, but how do we create really smart partnerships moving forward.

Yeah. Puneet, to address your questions on what this means from a financial perspective, we've always had a baseline level of investment in Alzheimer's diagnostics, frankly, for the last three or four years at this point. What we're doing in this plan right now is being very, very deliberate on where our investments go. We've streamlined projects in other parts of the business where perhaps that payback was not as immediate as these are, and that's what's helping us fund both the commercial acceleration as well as the acceleration in the diagnostics platform. From a revenue perspective, as you know, we did almost $10 million of revenue from our partners in 2025. Our expectation is that we'd have about the same level in 2026. We'll probably have less instrument sales, but an increase in consumable sales as our partners start to do more tests.

We're not counting on revenues from direct testing in 2026. We think it'll take some time for that to inflect. If that happens sooner, that'll be, you know, helpful to us, but we're not counting on that picking up very quickly.

Puneet, your, the last part of your question in terms of, you know, how do you balance both. You know, my first three months here, I've had a lot of interaction with our commercial colleagues, with Ben Meadows, our new Chief Commercial Officer. We have a solid-Research business, research tools business. The relationships that they have with the customers in the academic space and the research space, it's really, really deep, and we're going to help them get even deeper with the enhancements that I talked about during my remarks. It's an and, we're gonna build up that same expertise on the diagnostics side.

You know, today we have the appropriate size of our diagnostics business just based on where we are. The new leader that's coming in will build a plan that will assume, again, FDA clearance, we have a good price crosswalk. We're gonna get scalable reimbursement. We will be able to toggle very quickly to build out scale in our diagnostics. We're gonna balance on both research, tools, and diagnostics.

And we have another-

Puneet, are you still there or why don't we go to the next question, please?

Yeah. The next question comes from the line of Dan Brennan with TD Cowen. Please go ahead.

Great. Thank you. Thanks for the questions. Maybe first one just, it was already kind of asked in one way in terms of the guide. If you're kind of flattish in Q2, it implies almost like a 40% back half sequential, like second half, first half. Could you just break down a little bit more what would be the drivers of that? Do you wanna share any color, maybe instruments, consumables, and service, maybe core Quanterix versus spatial? I can have a few more questions. Thank you.

Yeah, Dan, let me talk about the investments that we're making, that these aren't investments that have a, you know, a year ROI. You know, I'm just taking this from my past experience of, hey, we need to build out momentum, you know, within the next few quarters. These are the investments that we're making. Let me just maybe give a couple of them color to give confidence of our second half ramp. Our lead generation reps are critical to our growth. Our lead generation reps are working with our marketing team and taking our robust leads that we have and making them credible, making phone calls to ensure that when they hand them over to our sales reps, those leads are ready to buy.

We've already instituted lead generation reps, and in the first 3 weeks, we're seeing a marked difference in terms of net new opportunities. I look at, in the second half, our net new opportunity growth to be absolutely better than it was in Q1. Secondly, our marketing. We have appropriately put investment in marketing on both the Simoa and spatial side of the business to develop more of a multi-channel approach. I always like to say we're selling when people are sleeping. We feel that that's gonna be a major benefit, you know, to our business. Then lastly, what I'll add is, you know, we are looking strategically at areas to where we could put just more feet on the street on the commercial team today.

Like I said, Ben Meadows and team have done a good job of, again, not overhauling, so we create disruption, but strategically putting more feet on the street so we can get at more opportunities in the second half.

I think the only thing I'd add there, Dan, is there's also a lot happening on the product side. We recently announced a new molecular barcoding option for customers, which gives our spatial customers a whole new channel for self-serve opportunities on the assays. We also have a handful of assay launches, as we generally do, that are now coming online and are expected to have more of an impact in the second half of the year.

Great. Okay. Are you guys assuming end markets improve as part of the outlook? Obviously, it's been challenging, but, you know, we've heard various signs of things getting a little bit better here. Just wondering how you think about that as you contemplate, like, the improvement, in addition to, obviously, all the critical, company-specific things you're doing?

Yeah. On the end markets, on the pharma side, you know, we do think that the end markets are strong. It's really been a little bit of the focus that's been lacking on our side, which we've already started to correct, and we're starting to see the results on. The academic side was a little bit slow in the first three, four months of the year. As you know, overall funding slowdown has been a little bit slow. You know, we're not counting on a big rebound over there, but we do think there might be a small amount of improvement as we get towards the end of the year. We're not assuming markets change materially. We're really assuming that a lot of the growth is gonna happen from our actions, both on the product side as well as on the commercial side.

The only thing I'll add, again, just from an execution standpoint, in the first quarter to start of the second quarter, the communications, the sales calls, the KOL, you know, kind of interaction has been very, very solid on our side. We're not waiting for markets to improve. I think those conversations, that consistent, you know, relationship connection that we have with our critical customers, when markets do improve, we will be there to capitalize on that.

Great. Then you list, I think, four studies in the press release or maybe in the deck. Are any of those going to I mean, obviously, I'm sure they're all important, otherwise you wouldn't have listed them. Do any of them stand out more than not in terms of either that'll play into FDA, play into the label, or will they all just be pieces of the puzzle as you build, you know, the marketing plan on your diagnostic assay?

Yeah. Listen, I like the studies that we have. First of all, they're with three credible partners. The study dynamics that I've been reviewing on a weekly basis, you know, we're hitting really good enrollment. The settings are mostly in that where people are being treated in the specialty care and primary care setting. It demonstrates how LucentAD Complete changes clinical decision-making and patient outcomes. We're looking at the right things from a clinical utility everyday diagnostic standpoint. I will also add, too, I'm excited about the timing. The timing is spot on for us to read out in the second half of 2026, and that will just bolster our meetings with payers to get, you know, widespread reimbursement.

If I can sneak one final in, just on the spatial side for Akoya, since you do break it out, like, is there an implicit assumption, and maybe you've already done this at 4Q when you set the initial guidance, but how are you thinking about kind of the contribution organically for spatial in 2026? Thanks a lot.

Yeah. We didn't break out the guide between Simoa and spatial just because, you know, we are starting to kind of report them all together. Our expectation of mix between Simoa and spatial between 2025 and 2026 looks relatively consistent, though.

Terrific. Thank you very much.

Thank you. There are no further questions at this time. Ladies and gentlemen, this now concludes today's conference call. Thank you all for joining. You may now disconnect.

Ladies and gentlemen, thank you for standing by. My name is Colby, and I will be your conference operator today. At this time, I would like to welcome you to the Quanterix Corporation Q4 2025 Earnings Call. [Operator Instructions] I will now turn the call over to Joshua Young. You may begin.

Thank you, Colby, and good afternoon, everybody. With me on today's call are Everett Cunningham, Quanterix President and CEO and Vandana Sriram, Quanterix Chief Financial Officer. Today's call is being recorded, and a replay of the call will be available on the Investor Relations section of our website. During the course of today's presentation, we will make forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act. These forward-looking statements are based on management's beliefs and assumptions as of today, March 2, 2026. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. To supplement our financial results presented on a GAAP basis, we have provided certain non-GAAP financial measures. These non-GAAP measures are used to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that such measures are important in comparing current results with other periods results in assessing our operating performance within our industry. Non-GAAP financial information presented herein should be considered in conjunction with and not as a substitute for the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to the most directly comparable GAAP financial measures set forth in the presentation posted to our website and in our earnings release issued earlier today. Finally, any percentage changes we discuss will be on a year-over-year basis, unless otherwise noted. Now I'd like to turn the call over to Everett Cunningham. Everett?

Thanks, Josh. And I'm so excited to be with you this afternoon. I'm looking forward to meeting many of you over the coming weeks and months. Now for those of you that I have not met, I want to share some information about my background and what brought me here to Quanterix I've spent my entire 3-decade-plus career in health care with a diverse background in pharma, tools and diagnostics from a variety of commercial and enterprise operational roles which is very relevant for where Quanterix is and as we scale our business. Now in my last role as the Chief Commercial Officer at Illumina. I led the commercial strategy and execution for this $20 billion market cap company as we go deeper into sequencing and array-based solutions. During my tenure at Illumina, I work with the team that delivered one of the most transformational technologies in the analytical instruments market. Now my work there built on my experience as a Chief Commercial Officer at Exact Sciences, where my team encompass sales, marketing and customer service in precision oncology diagnostics and screening. Now my prior roles at Quest, GE Healthcare and Pfizer effectively round out my commercial and my operational portfolio and combined, provide you with the insights needed to accelerate Quanterix' overall growth. Now I believe that Quanterix is well positioned to achieve a leadership position in the diagnostics industry. And I'm just very excited to work with my colleagues to achieve our commercial and our financial goals. Now there are several reasons why I'm very excited to be leading Quanterix at this time. First, Quanterix has developed differentiated technologies in disease states that need health care breakthroughs and also need solid business partnerships in neurology, oncology and immunology. Second, we have a compelling base business in the research tool space that exceeded our expectations in the fourth quarter and will drive us to breakeven profitability this year. Now this continued operational rigor will also provide a steady normalized growth path. Third, there's a massive opportunity for growth in the diagnostics market, starting with Alzheimer's disease, and Quanterix' ultrasensitive platforms are uniquely positioned here. Next, we have a strong foundation here at Quanterix, including a talented and dedicated team and a solid balance sheet with more than $100 million of cash and no debt. And lastly, I'm just thrilled to be joining Quanterix at this inflection point. I'm also looking forward to leading this company this year and beyond. Now my immediate focus area will be to spend as much time as possible with my leadership team and the employee base to fully understand Quanterix' potential from an insider's perspective and to ensure that our culture supports our priorities. I also fully need to understand the business and technology from a customer and strategic partner vantage point. So I'll be spending a lot of time with customers and partners, too. Now my objective is to continue to focus on what's working well and to evolve Quanterix into a stronger, more agile and scalable company. Now that entails fully understanding where we are the strongest and have the best opportunities to win, working together with our team and drawing on my years of experience in this field to guide our direction forward. I also want to establish an open and transparent communication process with our analysts and investors. I'm sure that many of you have a range of ideas and insights about our path forward, and I welcome your ideas. We will, of course, keep you updated as we move forward. So now let me turn it over to our Chief Financial Officer, Vandana Sriram. Vandana.

Thank you, Everett, and good afternoon. Total revenue for the fourth quarter was $43.9 million, an increase of 25% from the previous year and up 7% sequentially. Organic revenue was a decline of 22%. Revenue from our diagnostics partners was $3.1 million in the quarter. During the quarter, we saw better-than-expected revenues from the release of pent-up demand from our academic customer base. From a product perspective, Simoa contributed $27 million, a 22% organic revenue decline and Spatial reported $17 million, down 23% year-over-year. Spatial revenues include $2.5 million from a diagnostics development agreement that is now terminated. Excluding this agreement, Spatial revenues were down 16% year-over-year. The terminated agreement was dilutive to the company's financial results and will have a minimal impact on our core business in 2026. Instrument revenue was $6.1 million, comprised of $3.2 million of Simoa and $2.9 million Spatial instruments. We placed 21 Simoa and 17 Spatial instruments in the quarter, as compared to 18 Simoa instruments in the fourth quarter of 2024. Consumables revenue was $23 million, up $3.8 million sequentially. This consisted of $15.4 million in Simoa and $7.6 million in Spatial consumables. Accelerator lab revenue was $8.3 million, $5.3 million in Simoa and $3 million in Spatial. Our customer mix was slightly skewed to academia, which represented approximately 55% of the business in Q4. On a pro forma basis, assuming Quanterix and Akoya will combined for the full year, academic revenue for the fourth quarter declined approximately 24%. Pharma revenue declined 21% year-over-year primarily due to lower large accelerator projects versus the prior year. From a diagnostics perspective, we now have 25 partnerships that generated $9.6 million in revenue during 2025, up from $6 million in the prior year. This includes our recently announced partnership with Life Line Screening a national health screening group focused on identifying asymptomatic risks for chronic conditions in a community health setting. We continue to deliver key milestones in our Diagnostics business as we execute our long-term strategy. Our LucentAD complete test, which is a multi-analyte algorithmic blood test for Alzheimer's disease remains a highly differentiated test in the market. We recently achieved 2 significant milestones for LucentAD complete. Firstly, in Q4, the centers for Medicare and Medicaid services approved a reimbursement rate of $897 for the test. This milestone provides a nationally recognized reference price for the test. We are now focused on generating clinical utility data in support of LucentAD complete in various payer conversations. Secondly, in January 2026. We submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for this test. Both these milestones further our mission to provide superior, noninvasive, high-performance diagnostics tools to aid in the evaluation of patients with cognitive symptoms for possible Alzheimer's disease. During 2025, we also launched 13 new assays, including 2 new Simoa Tau assays, pTau-205 and pTau-212. We have seen strong interest in both products during the initial launch period. In the coming year, we expect Tau biomarkers to remain of high interest and plan to launch additional products addressing this growing field. On the Spatial side of the business, we launched 2 new PhenoCode Discovery panels in Q4 25, a metabolism spike in panel and a mouse neurology panel. The mouse neurology panel expands our Spatial biology and neurology offerings into mouse models and complements our previously launched human neurology panel. Moving on to the P&L. Gross profit and margin for the fourth quarter was $20 million or 45.7%. Non-GAAP gross profit was $21.9 million and non-GAAP gross margins 50%. Operating expenses for the quarter were $44.8 million. Included in operating expenses are approximately $6.4 million of costs related to acquisition, integration, restructuring and purchase accounting and $1.4 million of shipping and handling costs. Non-GAAP operating expenses were $37 million a decrease of roughly $1.5 million sequentially as a result of synergies. As Everett mentioned, we've completed major integration activities and are turning our attention to profitable growth and delivering on our commitment to be cash flow breakeven in 2026. We have already implemented $74 million of our $85 million cost synergy target, and we're on track to meet our target by the end of Q1. Additionally, we remediated our material weaknesses related to revenue and inventory. By putting these material weaknesses behind us, we have established a stronger foundation for future growth. Our adjusted EBITDA was a loss of $7.9 million, a sequential improvement of $4 million as compared to a loss of $11.9 million in the third quarter. We ended the quarter with $122 million of cash, cash equivalents, marketable securities and restricted cash. During the quarter, we made a $10 million milestone payment for the EMISSION acquisition and spent $3.5 million related to severance and other nonrecurring expenses. Adjusted cash usage during the quarter was $3 million compared to $16.1 million in Q3, a marked sequential improvement as a result of synergies and improved working capital. I will now turn to our guidance for 2026. We expect to report approximately $169 million to $174 million of revenue, which assumes no underlying improvement in the academic or pharmaceutical end markets. In 2026, we expect a minimal impact to our core business from the terminated diagnostics development agreement, which yielded $5.6 million of revenue for the full year of 2025. Excluding this agreement, we expect pro forma revenue for 2026 to increase by approximately 2% at the midpoint of the guide. We expect GAAP gross margin to be in a range of 45% to 49% and non-GAAP gross margin to be in a range of 49% to 53%. We anticipate achieving cash flow breakeven in the second half of the year and expect to end the year with approximately $100 million of cash and no debt. And finally, in terms of our quarterly cadence, we expect similar seasonal pacing to revenue as in prior years. I will now turn it back over to Everett for closing remarks.

Thanks, Vandana. I'm confident in our base business. I'm also confident in our plan for breakeven profitability this year. And lastly, I'm confident in scaling our business into areas of profitable growth. Now I want to turn it back over to Josh.

Thank you, Everett. Colby, please assemble the Q&A roster.

[Operator Instructions] Your first question comes from Kyle Mikson with Canaccord Genuity.

This is Alex Vukasin on the line for Kyle Mikson. Congratulations, Everett on the new role. We look forward to working with you. This one is for Everett. So in your assessment of Quanterix' core high sensitivity proteomics as well as Spatial Biology businesses, what do you see the company has been executing on effectively? And additionally, what are some aspects of the current strategy that you would like to adjust or change with these 2 businesses in the near term?

Yes. No, thanks for that question. I'm looking forward to working with you also. As I come on, I've been now with the company for 35-plus days, and I'm taking this opportunity to really assess our diversified strategy, which I love. I'll mention a couple of stats about what Akoya has done in our Spatial business, before Akoya we were, what, 90% neurology, 10% oncology immunology. Now with Akoya and the Spatial technology and expertise we're now more diversified. We're now 60% neurology and plus 40% Spatial and oncology and immunology. So I like that diversification. What I like is that, I like the fact that they have a broad footprint. I like the talent that the business has brought on to Quanterix. I also like the fact that there's been a lot of work around synergy targets and making sure that we can take advantage of that, as you heard from Vandana, we will hit our $85 million target at the end of Q1. Now what that's going to allow us to do, it's going to allow us to really focus on how do we now execute our growth plan in the Simoa space, but also in the Akoya Spatial space. And the footprint, the technology that they bring on, the customer relationship that they have, I think really makes us really appropriate to drive our growth strategy this year and beyond.

Got it. And just one more for me. So you noted earlier on the call that you launched about 13 new assays in 2025 alone. On the pipeline, any new asset or new product launches for 2026? And more specifically, what is the timing for the more general availability of your higher plex Simoa ONE platform? Any feedback from the early access program that gives you confidence this new platform and its capabilities could drive greater proteomics performance in the near term?

I'll have Vandana take the first, and I'll take the Samoa ONE question second.

Alex, you're right. We did 13 assays in 2025. We did about 20 assays in 2024 before that. This is really an indicator of the fact that our innovation engine is now moving and we expect to have a regular cadence of assay launches every quarter. We have a couple that are already in the pipeline for Q1 that will be coming out shortly, but the intent really is that this is a continuous stream throughout 2026.

Yes. And as far as Simoa ONE, we rolled out our early access program for Simoa ONE at the end of last quarter. And right now, what we're doing is we're currently executing the test plans with our customers. So we're going to continue to gather feedback and that feedback will actually steer our decision-making. The benefit of me taking over recently is, I'm also in the process of doing a holistic review of all of our product development and launch initiatives here at Quanterix. I will say this. We have attractive segments on both sides, the Samoa and the Spatial side. The one thing that we will have to do because of that attractive segments, we'll have to make some decisions. And our decision will be based on return on investment and bringing growth back to Quanterix as quickly as possible.

Your next question comes from the line of Puneet Souda with Leerink Partners.

First one, Everett for you. You emphasized Alzheimer's diagnostics. Obviously, you're coming with significant experience in sales and commercial side. So I wanted to get a view from you going forward, as you talked about the diagnostics opportunity, how should we think about the overall prioritization or when you look at the diagnostics versus the Simoa proteomics versus the Spatial business that you have? And how are you thinking about those 3 segments and also, if you can provide an expectation for the investments needed to drive growth on the Alzheimer's diagnostic side? Can you still reach the cash flow breakeven expectation by the year-end after the addition of those sales and commercial investments that you are potentially planning here?

Yes, Puneet, thanks for the question. I appreciate that. I'll touch on a few things and maybe have Vandana talk about the breakeven piece. I'm excited about the diagnostics opportunity. I spoke about it in my initial remarks. And we're well -- really set up to make an impact in the Alzheimer's diagnostics opportunity. As Vandana said, we had a good price crosswalk from CMS. We had our CMS approved pricing like I said, of $897 per LucentAD. We now have several ongoing clinical utility studies for LucentAD, and we look to work with 3 organizations, 2 in academia and then as we track the results, we're looking for releasing those results in the second half of this year. What that's going to do is that will really guide us with our payer engagement and reimbursement strategies. From my past, I've learned that you really need to get the payers on board, good reimbursement scalable strategies that will allow for our customers to pull this amazing opportunity through. Now that's our Alzheimer's diagnostics opportunity. I also feel that we have an oncology diagnostics opportunity. But again, 35 days into this, give me time to really look into this, focus on it and really invest in how we bring that to market. Now the impact for that will probably be starting in '27, but I'll let Vandana talk about that.

Yes. Hey Puneet, in terms of our framework for investment in diagnostics, as you know, over the last couple of years, we've been somewhat pacing the market, but we've been putting in additional investments where needed. We already have a double-digit sales force that's out there that right now has been focused on partnerships, but very quickly is shifting their focus to really bringing LucentAD complete to the market. So in our cash plan for 2026, we have contemplated all of the work that will go into the reimbursement pathway, as well as into building the infrastructure required from an order to cash perspective, et cetera, to be able to support volume in that company. So our plan for now contains all of those relevant investments and still gets us to breakeven in that second half of the year. Now if the market were to move faster or things were to develop faster, those would be good problems to have in a way. And we would welcome speed of adoption in this area.

Got it. Okay. That's helpful. And then on the FDA submission side, can you just update us on any dialogue with FDA? What they're looking for -- sorry, you have a breakthrough designation earlier on. So I just wanted to get a sense of potential time line and approval of the product. It's good to see that you already have reimbursement, but just wanted to get a sense on feedback that you have received.

Yes. Thanks, Puneet. We're working very well with the FDA. Again, we submitted the 501(k) in January. We expect the approval to take anywhere between 6 to 9 months, and then we anticipate securing that same thing by Q4 of this year. But again, 6 to 9 months is what we're looking for. I think the most important thing around that, that Vandana said is working sequentially with waiting for the FDA approval, making sure that we have good order to cash within our own lab. And then I'd tell you that making sure that we have a good payer strategy around when we develop that clinical evidence. So we're excited about our surround sound strategy.

[Operator Instructions] Your next question comes from Tom DeBourcy with Nephron Research.

Sorry about that. Can you hear me?

Yes. We got you, Tom.

So I just wanted to understand your Accelerator Lab and lab services. It seems like Q4 was stronger than expected, maybe even particularly in Simoa. And so just in terms of the level of demand from pharma customers? And then as you look out, at least for the next first half of the year, have you seen the rebound in activity and demand for lab services, I guess the pipeline had previously, I guess, maybe run down a little bit there?

Yes. Let me take the Q4 question and then Everett and I will tag team on what we're seeing for Q1. So Q4, again, a strong finish to the year. We were generally very pleased with all of our sectors, consumables and lab services in particular. On the Simoa Accelerator side, as we've mentioned before in 2025, the interest for the offerings continue to remain strong. In Q4, we saw a handful of projects come to an end, and we also saw, again, a good diversity of projects that basically helped on the revenue side.

Yes. I like our Accelerator business. And I think my first week here, they were talking about how profitable our Accelerator business is. And we have a lot of good partnerships that are out there. Right now, my goal is to really understand our accelerated business. Our projects are about $50,000 on average. My goal is, I want to get bigger projects with pharma. I think there's an opportunity to do that with how important solving this Alzheimer's dilemma is. So we'll continue to invest in our Accelerator business. We'll establish broader partnerships with pharma, and it will be an opportunity for us to continue to grow that segment.

Thank you. With no further questions in queue, that concludes our question-and-answer session. Thank you all for joining. You may now disconnect.